Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
You may also be interested in...
Vaccines Unit Shines For GSK In 3Q
GlaxoSmithKline's vaccine's business, which has been under the spotlight this week following a US regulatory submission for its highly anticipated shingles vaccines, Shingrix, has come out shining in the third quarter – setting the stage for a strong full-year readout.
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.
Mylan Confident On Advair Generic First-Round Approval
President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.